Aclaris Therapeutics prices $50 million stock offering and releases positive Phase 1b data

Aclaris Therapeutics announced that it priced an underwritten offering of 7,785,714 shares at $3.50 per share, targeting gross proceeds of about $50 million. The company also disclosed Phase 1b proof‑of‑concept results for ATI‑052, showing a 45% placebo‑adjusted improvement in EASI score and a 43% itch‑score improvement in atopic dermatitis, and a 59% reduction in FeNO with a 200 mL FEV1 gain in asthma. The financing and data release prompted a decline in the ACRS share price.

The $50 million raise is intended to fund the planned Phase 2b eosinophilic esophagitis program and extend the cash runway, but the dilution contributed to a drop in the stock price.

  • 1The offering was priced at $3.50 per share.
  • 2A total of 7,785,714 shares were sold in the offering.
  • 3Gross proceeds are expected to be approximately $50 million before expenses.
  • 4Phase 1b data showed a 45% placebo‑adjusted improvement in EASI score for atopic dermatitis.
  • 5Itch relief improved 43% placebo‑adjusted in the same trial.
  • 6In the asthma trial, FeNO was reduced by 59% placebo‑adjusted and FEV1 improved by 200 mL placebo‑adjusted.
  • Material 5 reports the stock fell 7.7% after the announcement, while material 4 reports a 9.5% pre‑market decline and material 6 reports a 3% drop.

Sources